How would you treat rapidly growing inflammatory breast cancer, invasive lobular triple negative subtype, after two cycles of neoadjuvant KEYNOTE 522?

How would you approach treatment with systemic therapy, surgery, and radiation if there is evidence of little treatment response, tumor growth, and new inflammatory features in contralateral breast?

Answer from: Medical Oncologist at Academic Institution

This is probably the single most difficult subtype of breast cancer to treat as it tends to be horribly chemo insensitive and molecularly most are actually luminal B and not basal. If growing on the carbon/Taxol/pembro portion of KEYNOTE, I would switch immediately to AC/pembro with a low threshold ...

Please select the option that best describes you:

How would you treat rapidly growing inflammatory breast cancer, invasive lobular triple negative subtype, after two cycles of neoadjuvant KEYNOTE 522?

Related Questions